Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hetastarch is a synthetic colloid and plasma volume expander derived from waxy corn starch, primarily composed of the glucose polymer amylopectin. It is indicated for the treatment and prophylaxis of hypovolemia (low blood volume) when plasma volume expansion is desired, particularly in surgical settings where alternative treatments are unavailable. By increasing the oncotic pressure of the blood, hetastarch facilitates the movement of fluid from the interstitial space into the intravascular compartment, thereby maintaining hemodynamic stability. It is also used as an adjunct in leukapheresis to improve the yield of granulocytes during centrifugal harvesting. However, hetastarch carries a boxed warning due to increased risks of mortality and renal injury in critically ill adult patients, including those with sepsis, and is strictly contraindicated in these populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hetastarch.